{"transactions":[{"id":759070,"issuer":{"id":7869,"kind":"organization","name":"BRAINSTORM CELL THERAPEUTICS INC."},"owners":[{"id":43251,"kind":"person","name":"Yablonka Uri","position":1,"cik":"0001608814","reported_name":"Yablonka Uri","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & Chief Business Officer"}}],"security":"Common Stock","published_at":"2026-05-29T21:02:01.000Z","date":"2026-02-26","kind":"grant","planned":false,"acquired":true,"shares":150000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares of restricted stock units (\"RSUs\") awarded under the Plan. The RSUs shall vest as to (i) 50% of the award on the date of grant and (ii) the remaining 50% of the award shall vest on the six-month anniversary of the date of grant, provided that the Reporting Person remains employed by the Issuer through each applicable vesting date."}],"balance_after":218464,"source":{"system":"sec-edgar","filing":"0001104659-26-068338","document":"tm2615354-4_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1137883/000110465926068338/tm2615354-4_4seq1.xml","form_type":"4"}},{"id":1315840,"issuer":{"id":7869,"kind":"organization","name":"BRAINSTORM CELL THERAPEUTICS INC."},"owners":[{"id":43251,"kind":"person","name":"Yablonka Uri","position":1,"cik":"0001608814","reported_name":"Yablonka Uri","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & Chief Business Officer"}}],"security":"Common Stock","published_at":"2025-01-03T22:34:08.000Z","date":"2025-01-01","kind":"grant","planned":false,"acquired":true,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"Represents shares of restricted stock units (\"RSUs\") awarded under the Plan. The RSUs shall vest as to (i) 50% of the award on the date of grant and (ii) the remaining 50% of the award shall vest on the six-month anniversary of the date of grant, provided that the Reporting Person remains employed by the Issuer through each applicable vesting date."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Reflects the Issuer's 1-for-15 reverse stock split effected market open on October 1, 2024."}],"balance_after":68464,"source":{"system":"sec-edgar","filing":"0001104659-25-000892","document":"tm251864-7_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1137883/000110465925000892/tm251864-7_4seq1.xml","form_type":"4"}},{"id":1315839,"issuer":{"id":7869,"kind":"organization","name":"BRAINSTORM CELL THERAPEUTICS INC."},"owners":[{"id":43251,"kind":"person","name":"Yablonka Uri","position":1,"cik":"0001608814","reported_name":"Yablonka Uri","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & Chief Business Officer"}}],"security":"Common Stock","published_at":"2025-01-03T22:34:08.000Z","date":"2025-01-01","kind":"grant","planned":false,"acquired":true,"shares":40000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares of restricted stock awarded under the Issuer's 2014 Global Share Option Plan (the \"Plan\"). The shares of restricted stock shall vest as to (i) 50% of the award on the six-month anniversary of the date of grant and (ii) the remaining 50% of the award shall vest on the eighteenth-month anniversary of the date of grant, provided that the Reporting Person remains employed by the Issuer through each applicable vesting date."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Reflects the Issuer's 1-for-15 reverse stock split effected market open on October 1, 2024."}],"balance_after":48464,"source":{"system":"sec-edgar","filing":"0001104659-25-000892","document":"tm251864-7_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1137883/000110465925000892/tm251864-7_4seq1.xml","form_type":"4"}},{"id":1579173,"issuer":{"id":7869,"kind":"organization","name":"BRAINSTORM CELL THERAPEUTICS INC."},"owners":[{"id":43251,"kind":"person","name":"Yablonka Uri","position":1,"cik":"0001608814","reported_name":"Yablonka Uri","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & Chief Business Officer"}}],"security":"Common Stock","published_at":"2024-03-14T00:56:54.000Z","date":"2024-03-11","kind":"grant","planned":false,"acquired":true,"shares":109426,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The grant of restricted stock awards (\"RSAs\") to the Reporting Person as reported herein was approved by the board of directors of the Issuer on March 11, 2024 (\"Grant Date\") as part of the Issuer's grant of equity awards in the ordinary course. The RSAs shall vest in equal yearly installments over the course of two (2) years, with vesting occurring on each of the first and second anniversary of the Grant Date."}],"balance_after":126969,"source":{"system":"sec-edgar","filing":"0001104659-24-034093","document":"tm248822-3_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1137883/000110465924034093/tm248822-3_4seq1.xml","form_type":"4"}},{"id":2468046,"issuer":{"id":7869,"kind":"organization","name":"BRAINSTORM CELL THERAPEUTICS INC."},"owners":[{"id":43251,"kind":"person","name":"Yablonka Uri","position":1,"cik":"0001608814","reported_name":"Yablonka Uri","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2021-12-17T22:01:38.000Z","date":"2021-12-15","kind":"grant","acquired":true,"shares":13333,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Option vests and become exercisable in 12 consecutive, equal monthly installments commencing on January 15, 2022 until fully vested and exercisable on the 12 month anniversary of December 15, 2021."}],"balance_after":13333,"derivative":{"exercise_price":0.75,"expiration_date":"2031-12-15","underlying":"Common Stock","underlying_shares":13333},"source":{"system":"sec-edgar","filing":"0001104659-21-151211","document":"tm2135659-2_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1137883/000110465921151211/tm2135659-2_4seq1.xml","form_type":"4"}},{"id":2477584,"issuer":{"id":7869,"kind":"organization","name":"BRAINSTORM CELL THERAPEUTICS INC."},"owners":[{"id":43251,"kind":"person","name":"Yablonka Uri","position":1,"cik":"0001608814","reported_name":"Yablonka Uri","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2021-12-11T01:01:33.000Z","date":"2021-12-10","kind":"grant","acquired":true,"shares":13333,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"In connection with the Company's 2020 Annual Meeting of Stockholders, pursuant to the Company's Second Amended and Restated Director Compensation Plan, as amended, option vested and became exercisable in 12 consecutive, equal monthly installments commencing on December 11, 2020 until fully vested and exercisable on the 12 month anniversary of November 11, 2020, provided that the Reporting Person remained a member of the Board of Directors of the Issuer on each vesting date."}],"balance_after":13333,"derivative":{"exercise_price":0.75,"expiration_date":"2031-12-10","underlying":"Common Stock","underlying_shares":13333},"source":{"system":"sec-edgar","filing":"0001104659-21-148747","document":"tm2135032-2_4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1137883/000110465921148747/tm2135032-2_4.xml","form_type":"4"}},{"id":3099167,"issuer":{"id":7869,"kind":"organization","name":"BRAINSTORM CELL THERAPEUTICS INC."},"owners":[{"id":43251,"kind":"person","name":"Yablonka Uri","position":1,"cik":"0001608814","reported_name":"Yablonka Uri","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & Chief Business Officer"}}],"security":"Common Stock","published_at":"2020-06-26T21:00:45.000Z","date":"2020-06-23","kind":"grant","acquired":true,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":17543,"source":{"system":"sec-edgar","filing":"0001104659-20-077512","document":"tm2023245d1_4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1137883/000110465920077512/tm2023245d1_4.xml","form_type":"4"}},{"id":3271036,"issuer":{"id":7869,"kind":"organization","name":"BRAINSTORM CELL THERAPEUTICS INC."},"owners":[{"id":43251,"kind":"person","name":"Yablonka Uri","position":1,"cik":"0001608814","reported_name":"Yablonka Uri","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP and Chief Business Officer"}}],"security":"Stock Option (right to buy)","published_at":"2020-02-14T22:00:26.000Z","date":"2019-12-12","kind":"grant","acquired":true,"shares":13333,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Option vests and becomes exercisable in 12 consecutive, equal monthly installments commencing on January 12, 2020 until fully vested and exercisable on December 12, 2020, provided that the reporting person remains a director of Brainstorm Cell Therapeutics on each vesting date."}],"balance_after":13333,"derivative":{"exercise_price":0.75,"exercise_date":"2020-01-12","expiration_date":"2029-12-12","underlying":"Common Stock","underlying_shares":13333},"source":{"system":"sec-edgar","filing":"0001104659-20-021985","document":"tm205737d5_4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1137883/000110465920021985/tm205737d5_4.xml","form_type":"4"}},{"id":3747798,"issuer":{"id":7869,"kind":"organization","name":"BRAINSTORM CELL THERAPEUTICS INC."},"owners":[{"id":43251,"kind":"person","name":"Yablonka Uri","position":1,"cik":"0001608814","reported_name":"Yablonka Uri","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP and Chief Business Officer"}}],"security":"Stock Option (right to buy)","published_at":"2018-11-30T22:03:45.000Z","date":"2018-11-30","kind":"grant","acquired":true,"shares":13333,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Option vests and becomes exercisable in 12 consecutive, equal monthly installments commencing on December 30, 2018 until fully vested and exercisable on November 30, 2019, provided that the reporting person remains a director of Brainstorm Cell Therapeutics on each vesting date."}],"balance_after":13333,"derivative":{"exercise_price":0.75,"exercise_date":"2018-12-30","expiration_date":"2028-11-30","underlying":"Common Stock","underlying_shares":13333},"source":{"system":"sec-edgar","filing":"0001144204-18-062651","document":"tv507902_4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1137883/000114420418062651/tv507902_4.xml","form_type":"4"}},{"id":4165949,"issuer":{"id":7869,"kind":"organization","name":"BRAINSTORM CELL THERAPEUTICS INC."},"owners":[{"id":43251,"kind":"person","name":"Yablonka Uri","position":1,"cik":"0001608814","reported_name":"Yablonka Uri","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP and Chief Business Officer"}}],"security":"Stock Option (right to buy)","published_at":"2017-11-13T21:37:42.000Z","date":"2017-11-10","kind":"grant","acquired":true,"shares":13333,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Option vests and becomes exercisable in 12 consecutive, equal monthly installments commencing on December 10, 2017 until fully vested and exercisable on November 10, 2018, provided that the reporting person remains a director of Brainstorm Cell Therapeutics on each vesting date."}],"balance_after":13333,"derivative":{"exercise_price":0.75,"exercise_date":"2017-12-10","expiration_date":"2027-11-10","underlying":"Common Stock","underlying_shares":13333},"source":{"system":"sec-edgar","filing":"0001144204-17-058399","document":"tv479019_4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1137883/000114420417058399/tv479019_4.xml","form_type":"4"}},{"id":4226726,"issuer":{"id":7869,"kind":"organization","name":"BRAINSTORM CELL THERAPEUTICS INC."},"owners":[{"id":43251,"kind":"person","name":"Yablonka Uri","position":1,"cik":"0001608814","reported_name":"Yablonka Uri","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & Chief Business Officer"}}],"security":"Common Stock","published_at":"2017-08-23T18:22:51.000Z","date":"2017-08-23","kind":"purchase","acquired":true,"shares":2000,"price":3.98,"value":7960.0,"ownership":{"direct":true},"balance_after":7543,"source":{"system":"sec-edgar","filing":"0001144204-17-044724","document":"v473922_4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1137883/000114420417044724/v473922_4.xml","form_type":"4"}},{"id":4256545,"issuer":{"id":7869,"kind":"organization","name":"BRAINSTORM CELL THERAPEUTICS INC."},"owners":[{"id":43251,"kind":"person","name":"Yablonka Uri","position":1,"cik":"0001608814","reported_name":"Yablonka Uri","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & Chief Business Officer"}}],"security":"Common Stock","published_at":"2017-07-17T21:00:21.000Z","date":"2017-07-13","kind":"grant","acquired":true,"shares":5543,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":5543,"source":{"system":"sec-edgar","filing":"0001144204-17-037012","document":"v470768_4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1137883/000114420417037012/v470768_4.xml","form_type":"4"}}]}